Encaleret for Rare ADH1 Gets FDA Fast Track Designation

Encaleret for Rare ADH1 Gets FDA Fast Track Designation

296023

Encaleret for Rare ADH1 Gets FDA Fast Track Designation

The U.S. Food and Drug Administration has granted fast track designation to encaleret, an investigational therapy for autosomal dominant hypocalcemia type 1, called ADH1, a rare genetic form of hypoparathyroidism. Encaleret is designed to help normalize the calcium levels of ADH1 patients by blocking the calcium-sensing receptor known as CaSR. People with ADH1 carry mutations in the CASR gene that result in a receptor that interprets low calcium levels as normal. “Balancing near-normal blood and…

You must be logged in to read/download the full post.